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Evaluation of Twenty-One Human Adenovirus Types
and One Infectivity-Enhanced Adenovirus for the
Treatment of Malignant Melanoma
Dennis Hoffmann1, Wibke Bayer1, Albert Heim2, Anja Potthoff3, Dirk M. Nettelbeck4,5 and Oliver Wildner1
Advanced melanoma is associated with poor prognosis warranting the development of new therapeutics, such
as oncolytic adenoviruses for immunovirotherapy. Since this approach critically depends on efficient
transduction of targeted tumor cells, we screened a panel of 22 different adenovirus types for their
internalization efficiency in melanoma cells. We demonstrated that the virions of Ad35, Ad38, and Ad3 have
significantly higher internalization efficiency in melanoma cells than Ad5, so far the only adenovirus type used
in clinical trials for melanoma. Therefore, we developed a conditionally replication-competent Ad5-based
vector with the Ad35 fiber shaft and knob domains (Ad5/35) and compared its therapeutic efficacy with the
homologous vector carrying the native Ad5 fiber. To further enhance virotherapy, we combined the oncolytic
adenovirus vectors with intratumoral expression of measles virus fusogenic membrane glycoproteins H and F
(MV-H/F) and dacarbazine chemotherapy. In a human melanoma xenograft model, established from a short-
term culture of primary melanoma cells, we demonstrated that the Ad5/35-based therapy had a significantly
greater anti-neoplastic effect than the homologous Ad5-based therapy. Furthermore, the combination of
virotherapy, intratumoral expression of MV-H/F, and chemotherapy was clearly superior to single- or double-
agent therapy. In conclusion, Ad35-based vectors are promising for the treatment of melanoma.
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INTRODUCTION
Malignant melanoma accounts for B4% of skin cancer, but
causes B79% of skin cancer deaths (Johnson et al., 1995;
Jemal et al., 2007). Since current therapies have only limited
success in the treatment of patients with advanced melano-
ma, novel treatment strategies have been evaluated, such as
gene therapy. Recombinant adenoviruses are often used as
gene transfer vectors since they can in vivo infect both
dividing and non-dividing cells and usually express thera-
peutic genes at high levels (Wilson, 1996). Although there are
51 human adenovirus types, which are divided into six
species (A–F) (Lukashok and Horwitz, 1998), for gene therapy
and recombinant vaccine trials, human adenovirus type 5
(Ad5), which belongs to species C, has been most often used.
Adenovirus particles are non-enveloped, icosahedral in
shape with their fiber protruding from each of the 12 vertices,
called penton base. The fibers are trimers with long tails and
globular head regions, referred to as the knob domain, which
binds to the cellular adenovirus receptor. For many adeno-
virus types, the functional cellular receptor has not yet been
identified (Zhang and Bergelson, 2005). The coxsackie-
adenovirus receptor (CAR), a transmembrane compound of
tight junctions (Cohen et al., 2001), is the functional receptor
for species C adenoviruses (Bergelson et al., 1997; Tomko
et al., 1997). CD46, a ubiquitously expressed membrane
protein with complement regulatory functions, has recently
been identified as a cellular receptor for all species B
adenoviruses (Gaggar et al., 2003; Segerman et al., 2003b;
Sirena et al., 2004) except types 3 and 7 (Segerman et al.,
2003a; Marttila et al., 2005), and some species D adeno-
viruses, such as Ad37 (Wu et al., 2004) and Ad49 (Lemckert
et al., 2006). A series of data suggests the existence of an
additional species B adenovirus receptor (Tuve et al., 2006).
Following attachment, the penton base facilitates adenovirus
entry by binding to cell surface integrins anb3 or anb5 through
conserved Arg-Gly-Asp (RGD) motifs in the penton base,
leading to receptor-mediated endocytosis of the virion
(Wickham et al., 1993; Meier and Greber, 2004). The
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therapeutic efficacy of Ad5-based vectors critically depends
on the expression of CAR on the tumor cells (Li et al., 1999;
Douglas et al., 2001; Hoffmann et al., 2007d, e). However,
analysis of a variety of primary tumors, including melanoma,
has demonstrated deficiencies of the functional receptor for
adenovirus (Hemmi et al., 1998; Nakamura et al., 2002; Volk
et al., 2003), which might explain the low gene transfer
efficiency in many human trials (Gomez-Navarro et al.,
1999). For CAR independent internalization in short-term
cultures of melanoma cells and permanent melanoma cell
lines, we analyzed in this study wild-type adenovirus types 3,
5, 7, 8, 9, 11, 16, 19, 20, 21, 22, 25, 27, 32, 34, 35, 37, 38,
49, and 50. In addition, we evaluated the internalization of
an Ad5-based vector with an RGD-containing peptide in the
HI loop of the fiber knob domain (Dmitriev et al., 1998),
which has previously been evaluated in the context of
melanoma (Okada et al., 2005; Xiong et al., 2005). Besides
Ad5-based vectors with the native fiber, Ad5 vectors with the
fiber knob domain of Ad3 (Ad5/3) (Volk et al., 2003) or Ad35
(Ad5/35) (Schmitz et al., 2006) have been evaluated in
preclinical melanoma models.
To improve the safety and the therapeutic index of
replication-competent adenovirus vectors, many unique
strategies have been developed in an attempt to achieve
tumor selectivity (Alemany et al., 2000; Wildner, 2003). In
the transcriptional targeting approach, viral genes that are
essential for viral replication (e.g. E1 and E4) are placed under
the control of promoters that are preferentially active in tumor
cells compared to the surrounding normal tissues (Fuerer and
Iggo, 2002; Hernandez-Alcoceba et al., 2002; Johnson et al.,
2002; Banerjee et al., 2004; Li et al., 2005; Hoffmann and
Wildner, 2006a). Another strategy to restrict viral replication
and spread to tumor cells is based on the complementary
defects approach, where cellular dysfunctions complement
viral defects. A representative of this group has a 24-bp
deletion in the E1A conserved region 2 domain (E1D24) that
is required for retinoblastoma protein binding and thus E2F
liberation (Fueyo et al., 2000). In the conditionally replica-
tion-competent vectors used in this study, Ad5/
35D24.Ki COX and Ad5D24.Ki COX, the adenovirus E1
and E4 gene products, are transcriptionally targeted by the
Ki67 and the cyclooxygenase-2 promoter, respectively. The
Ki67 promoter is preferentially active in proliferating cells
(Hoffmann and Wildner, 2006b) and the activity of the
cyclooxygenase-2 promoter is unregulated in gastrointestinal
cancer (Subbaramaiah et al., 1997), and melanoma cells
(Nettelbeck et al., 2003) among others. In addition, both
vectors encompass the E1D24 mutation, targeting vector
replication to proliferating cells and cells where the
cyclooxygenase-2 promoter is active.
To further enhance virotherapy, we combined in the
second step the identified adenovirus type with enhanced
internalization efficiency into melanoma cells with the
expression of measles virus fusogenic membrane glyco-
proteins H and F (MV-H/F). Intratumoral expression of viral
fusogenic glycoproteins leads to syncytia formation of
infected cells with adjacent cells, thereby increasing the
dispersion of viruses throughout the tumor, lateral spread of
the transgene, virus release and enhanced immunogenicity of
tumor cells (Bateman et al., 2000; Galanis et al., 2001;
Li et al., 2001; Ahmed et al., 2003; Nakamura et al., 2004).
We demonstrated previously in gastrointestinal cancer and
sarcoma cell lines that the expression of MV-H/F results in
synergistically enhanced cytotoxicity of clinically relevant
chemotherapy and in significantly improved survival in vivo
(Hoffmann et al., 2006, 2007d; Hoffmann andWildner, 2006c).
Since replication-competent adenovirus vectors have
significantly higher tumor transduction efficiency than their
homologous replication-defective counterparts (Dion et al.,
1996; Wildner et al., 1999a, b) and replication-competent
adenovirus vectors encoding MV-H/F cannot be generated
due to constraints of their packaging capacity, we trans-
complemented the replication-defective MV-H/F encoding
adenovirus with a replication-restricted oncolytic adenovirus
(Alemany et al., 1999; Lee et al., 2004; Wolkersdorfer et al.,
2004).
Among the tested panel of adenovirus types and one
infectivity-enhanced Ad5-based vector, Ad35 had the highest
internalization efficiency in short-term cultures of melanoma
cells. Based on this finding we compared the oncolytic
efficacy of a conditionally replication-competent Ad5-based
vector (Ad5/35) containing a chimeric fiber gene encoding
the Ad5 fiber tail and Ad35 fiber shaft and knob domains to
redirect the binding of the vector to the Ad35 receptor, with
an Ad5 vector, in each case alone or in combination with
intratumoral expression of viral fusogenic glycoproteins and/
or chemotherapy. The Ad5/35-based triple therapy was
clearly more effective than the homologous Ad5-based
therapy. To our knowledge, this is the first study evaluating
a large panel of wild-type human adenovirus types side by
side for gene therapy of melanoma.
RESULTS
All analyzed primary melanoma were CAR-negative and
CD46-positive
The therapeutic efficacy of virotherapy critically depends on
the transduction efficiency of the targeted tumor cells and
thus on their expression of the functional viral receptor on the
tumor cells (Li et al., 1999; Cripe et al., 2001; Douglas et al.,
2001; Witlox et al., 2002, 2004; Hoffmann et al., 2007d, e).
For clinical melanoma gene therapy studies up to now, only
human Ad5 has been evaluated as a gene transfer vector (Liu
et al., 2004; Inoue et al., 2006). However, it has been
reported that short-term cultures of melanoma cells often lack
CAR or express it only at very low levels, in contrast to
permanent cell lines (Hemmi et al., 1998; Nakamura et al.,
2002; Volk et al., 2003).
To avoid potential cell culture artifacts, we analyzed
sections of primary cutaneous melanoma lesions of five
patients by immunohistochemistry. In Figure 1 the results of
three representative patients are shown. All analyzed tumors
showed a strong positive staining with the melanoma-specific
antibody HMB45 (Gown et al., 1986), confirming the
cytological diagnosis of melanoma. In addition, in all
analyzed tumors, the CAR protein, the primary functional
cellular receptor of Ad5 (Bergelson et al., 1997; Tomko et al.,
www.jidonline.org 989
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1997), was absent on HMB45-positive melanoma cells. In
contrast, CD46, the cellular receptor for all species B (Gaggar
et al., 2003; Segerman et al., 2003b; Sirena et al., 2004) and
some species D adenoviruses (Wu et al., 2004; Lemckert
et al., 2006), was highly expressed.
Efficient in vitro infection of melanoma cancer cells with some
B and D species adenoviruses but not Ad5
After we demonstrated in situ that none of the analyzed
melanomas expressed CAR, we screened in the next step for
CAR independent infection a panel of adenoviruses. We
analyzed, as a parameter for infectivity, the internalization of
21 different adenovirus types and an Ad5-based virus with an
insertion of an RGD motif in the HI loop of the adenovirus
fiber knob in permanent melanoma cell lines (A375, Sk-
Mel2, 888) and short-term cultures of melanoma cells (pMel-
A1, pMel-L, pMel-M, pMel-P, pMel-S). As a control we used
the human lung carcinoma cell line A549, which can be
efficiently infected with human adenovirus (Giard et al.,
1973; Smith et al., 1986).
As shown in Figure 2a, the internalization efficiency of
primary melanoma cells with adenovirus types 35, 38, 3, 21,
49, 34, 7, and 22 virions was 46-, 38-, 37-, 35-, 30-, 26-, 15-,
and 10-fold enhanced compared to Ad5 (Pp0.05). In our
assay, the internalization efficiency of the Ad5lucRGD vector
was 11-fold enhanced compared to Ad5 with the native fiber
(Pp0.05).
Of the adenoviruses with the highest internalization
efficiency, two belonged to species B and three to species
D. In most cases, the adenovirus internalization in the short-
term cultures of melanoma cells was less efficient than of
permanent melanoma cell lines. As shown in Figure 2b, the
ratio of internalized adenovirus particles of short-term
melanoma cell cultures to A549 cells was 42 with
adenovirus types 35, 38, 3, 49, and 21, suggesting a
somewhat preferential infection of melanoma cells. In
addition, we used flow cytometry to determine the cell
surface density of the receptors CAR, CD46, and CD80 by
staining of melanoma cells with FITC-conjugated antibodies
(Figure 2c). These receptors can serve as cellular attachment
proteins by some of the tested adenovirus types. None of the
tested short-term cultures of melanoma cells expressed CAR,
in contrast to the tested permanent melanoma cell lines,
where the density of CAR was 1.9-fold higher than on A549
cells. Compared to A549 cells, the density of CD46 and
CD80 on the analyzed short-term and permanent melanoma
cell lines was in the range of 50–220%. Using firefly
luciferase encoding first generation adenovirus vectors
Ad5.Luc, Ad5lucRGD, Ad5/3.Luc, and Ad5/35.Luc (the last
two vectors are Ad5-based vectors with a chimeric fiber gene
Patient 1
MM (pT3)
Patient 2 
MM (pT2)
Patient 3 
MM (pT2)
HMB45
CAR
CD46
Figure 1. Immunohistochemical analysis of primary cutaneous malignant melanoma lesions. The diagnosis of malignant melanoma (MM) was confirmed
by positive immunostaining for HMB45 in melanocytes (Gown et al., 1986). Since treatment efficacy of adenovirus critically depends on the expression
on the primary cellular receptor, we stained for CAR and CD46. CAR is the functional cellular receptor of Ad5 (Bergelson et al., 1997; Tomko et al., 1997)
and CD46, the cellular receptor for all species B (Gaggar et al., 2003; Segerman et al., 2003b; Sirena et al., 2004) and some species D adenoviruses (Wu et al.,
2004; Lemckert et al., 2006). Three representative slides out of five patients with primary cutaneous melanoma are shown; original magnification 400.
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encoding the Ad5 fiber tail and Ad3 or Ad35 fiber shaft and
knob domains, respectively), we qualitatively confirmed
some of the data obtained with the virus internalization
efficiency (data not shown).
Based on these results we generated an Ad5/35 fiber
chimeric double heterologous promoter-controlled oncolytic
vector and a replication-defective Ad5/35 vector encoding
MV-H/F and their homologous counterparts with the native
Ad5 fiber (Figure 3).
Expression of MV-H/F synergistically enhances DTIC in vitro
Since we previously observed that the expression of MV-H/F
can synergistically enhance chemotherapy in gastrointestinal
cancer and sarcoma cells (Hoffmann et al., 2006, 2007d;
Hoffmann and Wildner, 2006c), we analyzed in vitro
whether the expression of MV-H/F encoded by a replica-
tion-defective fiber chimeric adenovirus vector Ad5/35.H/F
will also enhance the chemotherapeutic drug dacarbazine
(DTIC) in melanoma cells. The ED50 concentrations (fraction
of affected cells¼ 0.5) were calculated for each drug
(Table 1). To adjust for differences in the transduction
efficiency, we determined the titer for each cell line
individually. This provided the basis for the appropriate ratio
of Ad5/35.H/F and DTIC. The ratio was kept constant when
the agents were studied in combination. The interaction of
the agents was analyzed with the software CalcuSyn. The
1200
CAR
Long-term
A549 cells
melanoma cells
Short-term
CD46
CD80/86
CAR
CD46
CD80
SA1000
800
600
400
200
0
Ad
5l
uc
RG
D
Ad5lucRGD
Ad31
A549
Isotype
control
A375
Sk-Mel2
pMel-A1
pMel-L
pMel-M
pMel-P
pMel-S
888
Ad3
Ad16
Ad7
Ad21
Ad50
Ad11
Ad34
Ad35
Ad5/35-Luc
Ad5
Ad8
Ad9
Ad19
Ad20
Ad22
Ad25
Ad27
Ad32
Ad37
Ad38
Ad49
Ad
31
 +
Ad
3 
†(?
), ‡
Ad
16
 †
Ad
21
 †
Ad
50
 †
Ad
5 
+
Ad
9
Ad
20
Ad
22
Ad
25
Ad
27
Ad
32
Ad
38
Ad
49
Ad
19
 +
,#
 
Ad
8 
#
Ad
11
 †
Ad
35
 †
Ad
37
 †
, #
Ad
34
Ad
5/
35
-L
uc
Ad
7
N
um
be
r o
f v
ira
l p
ar
tic
le
s/
ce
ll
Species: A
Ratio of internalized virus
(short-term melanoma cells/A549 cells)
C DB1 B2
Mean fluorescence intensity
0
0 100 200 300 400 500
1 2 3 4
Figure 2. Analysis of internalization of adenovirus types. (a) Monolayers of permanent melanoma cell lines (A375, Sk-Mel2, 888) and of short-term cultures
of malignant melanoma cells (pMel-A1, pMel-L, pMel-M, pMel-P and pMel-S) were infected for 1 hour with equal amounts of 3H-thymidine-labeled
adenovirus types. To remove unbound or attached but not internalized VPs, cells were incubated at 371C for 30minutes with trypsin-EDTA and the number
of internalized virions per cell was determined by scintillation counting. Virus internalization of the analyzed permanent melanoma cell lines and of the
five short-term cultures of melanoma cells were grouped and presented as mean7SD from three independent experiments. A549 cells served as a control
for CARþ cells. The currently known primary adenovirus cellular receptors are indicated. (b) To analyze the data shown in (a), we determined the ratio of
adenovirus internalization efficiency in melanoma cells vs A549 cells. A ratio X1 suggests preferential infection of melanoma cells when compared to A549
cells. (c) Using flow cytometrical analysis, we determined the cell surface density of CAR, CD46, and CD80 on melanoma cells. The mean fluorescence intensity
correlates directly with the cell surface density of the receptors, which can mediate attachment of some tested adenovirus types.
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dose–effect curves and combination index (CI) plots are
shown in Figure 4. In the CI plots, values above 1 indicate
antagonistic drug effects, whereas those below 1 are
considered synergistic. A CI of 1 suggests additive effects of
both agents. The effects of drug combinations on the ED50
concentrations are presented in Table 1. The best results were
obtained with Ad5/35.H/F and DTIC in pMel-S. The dose of
Ad5/35.H/F and DTIC needed to achieve the ED50 was
reduced 21.3- and 246.5-fold, respectively, when compared
to single-agent treatment.
Treatment efficacy is dependent on infectivity that can be
further enhanced by MV-H/F expression in combination with
chemotherapy
To analyze whether efficacy of melanoma treatment corre-
lates with the infectivity of the vector, we compared the
treatment efficacy of a conditionally replication-competent
Ad5/35 vector with that of an otherwise identical Ad5 vector
in a subcutaneous pMel-S melanoma xenograft model in
nude mice. Furthermore, we analyzed whether the synergy
between MV-H/F expression and DTIC observed in the in
vitro cytotoxicity assays would also result in an enhanced in
vivo treatment efficacy alone or in combination with
oncolytic vectors. For this, animals were treated with the
replication-restricted oncolytic adenovirus Ad5/35D24.Ki 
COX or Ad5D24.Ki COX vector alone or in combination
with DTIC, and/or adenovirus vectors encoding MV-H/F
(Ad5/35.H/F or Ad5.H/F). We monitored tumor growth (data
not shown) and survival (Figure 5).
When compared to untreated animals, all treatment
regimens resulted in significant reduction of tumor volume
at day 14 and improved survival (Pp0.05). Furthermore,
animals receiving intratumoral injections of Ad5/35.H/F or
Ad5.H/F in combination with DTIC resulted in a significantly
enhanced treatment efficacy when compared to treatment
with the individual compounds, despite the limited transduc-
tion efficiency of the replication defective vectors encoding
the MV-H/F (Pp0.005). However, there were no long-term
survivors.
To enhance the fraction of tumor cells expressing MV-H/F,
we trans-complemented the replication-defective Ad5/35.H/F
or Ad5.H/F vector with the respective oncolytic vector Ad5/
35D24.Ki COX or Ad5D24.Ki COX. In combination with
DTIC, this triple therapy had the highest treatment efficacy
with a median survival of 46 and 77 days, respectively, and
was clearly better than treatment with its compounds as
single- or double-agent therapy (Pp0.001). At the end of the
observation period (day 80), eight animals were alive in the
chimeric fiber adenovirus-based triple agent treatment group.
In all treatment combinations, the anti-neoplastic efficacy of
the chimeric Ad5/35 vectors was significantly better when
compared to vectors with the native Ad5 fiber (Po0.001).
DISCUSSION
The primary goal of this study was to enhance the efficacy of
adenovirus-based therapy for melanoma, which critically
depends on the infection/transduction efficiency of the
targeted tumor cells and thus on the expression of cellular
receptors used in viral infection (Li et al., 1999; Douglas
et al., 2001; Hoffmann et al., 2007d). Currently, only human
Ad5-based vectors have been evaluated in clinical trials for
melanoma as gene transfer vectors with limited success (Liu
et al., 2004; Inoue et al., 2006). However, previously it has
Ki-67 promoter
Ad5/35Δ24.Ki•COX
Ad5Δ24.Ki•COX Ad5 fiber
Ad5.H/F
Ad5/35 fiber
Ad5 fiber
Ad5/35 fiberAd5/35.H/F
MV-H MV-F
IRES
COX-2 promoter
E1Δ24 ΔE3
ΔE3
E4
hTERT pro
Ad5
Ad5
Figure 3. Vector design. (a) Design of double heterologous promoter-
controlled oncolytic Ad5-based vectors. To target viral replication and lysis to
melanoma cells, the E1 and E4 gene regions, which are essential for
adenovirus replication, were placed under the transcriptional control of
indicated heterologous promoters. In addition, the vectors encompass a 24-bp
deletion in the E1A CR2 (E1D24) domain that is responsible for viral E1A
binding to the retinoblastoma protein as described previously (Fueyo et al.,
2000). We generated these oncolytic vectors as an Ad5/35 fiber chimera and
its homologous counterpart with the native Ad5 fiber. (b) Design of measles
virus fusogenic membrane proteins H and F (MV-H/F) encoding Ad5-based
vectors with chimeric Ad5/35 or native Ad5 fiber.
Table 1. Concentrations1 required to obtain 50%
cytotoxicity as single and double agent treatment
A375 SK-Mel2 pMel-S
Single agent treatment ED50 ED50 ED50
Ad5/35.H/F 154.0 83.0 13.5
DTIC 73.8 46.9 169.8
Double agent treatment DRI2 DRI2 DRI2
DTIC 63.3 52.3 246.5
Ad5/35.H/F 131.4 117.4 21.3
DRI , dose reduction index; DTIC, dacarbazine; ED50, median effective
dose (50% cytotoxicity).
1All concentrations are given in nM; the definition 6.022 1023 VPs per
liter=1mol l1 (Mittereder et al., 1996) was used to calculated the
molarity of the vector Ad5/35.H/F based on the assumption that one
plaque forming unit equals one biologically active molecule (virion).
2The DRI determines the magnitude of dose reduction allowed for each
drug when given in synergistic combination, as compared with the
concentration of a single agent that is needed to achieve the same effect
level.
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been demonstrated that short-term cultures of melanoma
cells do not express CAR (Hemmi et al., 1998; Nakamura
et al., 2002; Volk et al., 2003; Schmitz et al., 2006), the
functional cellular receptor of Ad5 (Bergelson et al., 1997;
Tomko et al., 1997). To circumvent the possibility of cell
culture artifacts, we analyzed in situ the expression of CAR
and CD46 in primary cutaneous melanoma lesions of five
patients. We detected in none of the analyzed lesions
significant expression of CAR on the melanocytes. In contrast,
CD46, the cellular receptor for all species B (Gaggar et al.,
2003; Segerman et al., 2003b; Sirena et al., 2004) and some
species D adenoviruses (Wu et al., 2004; Lemckert et al.,
2006), was abundantly expressed in all analyzed malignant
melanoma lesions. We confirmed the in situ immunohisto-
chemistry data by flow cytometric analysis of the short-term
cultures prepared from these melanoma lesions.
This study is conceptionally divided into two sections.
First, for CAR independent infection we analyzed in vitro in
the short-term cultures of melanoma cells and as a control
also in permanent melanoma cell lines the internalization of
21 different adenovirus types and an RGD fiber modified
Ad5-based vector. We demonstrated that Ad35, Ad38, Ad3,
Ad49, Ad21, Ad34, Ad7, Ad5lucRGD, and Ad22 virions
(ranked in descending order) have significantly higher
internalization efficiency when compared to Ad5. In most
short-term cultures of melanoma cells, the adenovirus
internalization efficiency was significantly reduced compared
to the tested permanent melanoma cell lines, which have
been in continuous culture for many years. This indicates that
the expression pattern of viral receptors on the surface of
melanoma cells has changed during passage of the cells in
culture. However, in contrast to CAR, the short-term cultures
used in this study strongly express anb3 and anb5 integrins
(Volk et al., 2003). In addition it has been reported that a
heparan sulfate proteoglycan-binding motif KKTK in the fiber
shaft can mediate adenovirus attachment (Smith et al., 2003).
In a study by Havenga et al. (2002), using a library of fiber-
chimeric adenovirus vectors to exploit the natural diversity of
human adenovirus tropism, the authors showed that Ad5/35
provided the highest transduction efficiency of melanoma
cells, supporting our data. The data are partially supported by
Schmitz et al. (2006), who demonstrated that an Ad5 vector
with an RGD- and Ad35 fiber has a higher transduction
efficiency than the parental vector with native Ad5 fiber, yet
here the vector with the RGD sequence resulted in enhanced
transduction of melanoma cells on a larger number of short-
term cultures than the Ad35-fiber vector. Adenovirus vectors
with Ad35 fiber have shown great promise, as they are able to
transduce many human cell types, including human hema-
topoietic progenitor cells, human dendritic cells, and primary
human tumor cells, with greater efficiency than the parental
Ad5 vectors (Shayakhmetov et al., 2000; Hoffmann et al.,
2007d, e).
To further enhance adenovirus-based virotherapy for
melanoma, we combined in the second part of the study
the conditionally replicating Ad5/35 vector with intratumoral
expression of MV-H/F. In previous studies, we demonstrated,
in short-term cultures of human gastrointestinal cancer and
sarcoma cells with the median-effect principle (Chou,
1991a), that the expression of MV-H/F and other viral
fusogenic membrane proteins synergistically enhanced cell
killing and significantly improved survival in preclinical
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Figure 4. Analysis of combined drug effects. Permanent melanoma cell lines (A375 and Sk-Mel2) and short-term cultures of melanoma cells (pMel-L and
pMel-S) were exposed in vitro for 36 hours to DTIC alone or in combination with the replication-defective adenovirus vector Ad5/35.H/F encoding measles
virus fusogenic membrane proteins H and F at a constant molar ratio. (a) Cytotoxicity was assessed by bioluminescence and dose–effect curves were
generated. (b) To quantitate the interaction between the treatments, CI vs cytotoxicity plots were generated from the median-effect plots (Chou and Talalay,
1984). For these curves, CIo1 defines a synergistic interaction and CI41 antagonistic drug effects. The straight line at the CI¼ 1 represents the additive effects
of both drugs. The CI values for the 50% effective dose (ED50) are indicated.
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tumor models (Hoffmann et al., 2006, 2007c, d; Hoffmann
and Wildner, 2006c). This effect was independent of
functional p53 and did not correlate with the degree of
syncytia formation (Hoffmann et al., 2007c). Furthermore, we
observed an enhanced induction of apoptosis via a mito-
chondrial death pathway controlled by Bcl-2 family proteins
and a strong induction of p53 expression. In addition, we
demonstrated a significantly enhanced caspase 3/7 activity
(Hoffmann et al., 2007c), and increased protein levels of heat
shock proteins 60, 70, and 90a (Hoffmann et al., 2006).
In this study, we demonstrated that the expression of MV-
H/F also in short-term cultures of malignant melanoma and
permanent melanoma cell lines synergistically enhances the
cytotoxicity of DTIC. Since advanced melanoma is relatively
resistant to therapy and the objective response rate to one of
the most active single-agent drugs, the alkylating substance
DTIC, is approximately 10–20%, and responses are usually
short-lived (Wagner et al., 2000), this might improve
therapeutic efficacy. In addition, we demonstrated in tumor
models in immunocompetent animals that this approach can
serve as an in situ tumor vaccine (Hoffmann et al., 2007a, b).
To determine whether the enhanced ability of Ad35 to infect
melanoma cells when compared to Ad5 translates into an
enhanced treatment efficacy, we used an Ad5-based vector
(Ad5/35) with a chimeric fiber gene encoding the Ad5 fiber
tail and Ad35 fiber shaft and knob domains to redirect the
binding of the vector to the Ad35 receptor. We evaluated the
oncolytic activity of Ad5/35D24.Ki COX and Ad5-
D24.Ki COX alone or in combination with MV-H/F expres-
sion and/or DTIC. The compared oncolytic adenovirus
vectors were identical with the exception of the fiber. We
establish a subcutaneous xenograft model in nude mice using
a short-term culture of primary human cutaneous malignant
melanoma cells designated pMel-S. In contrast to xenografts
derived from permanent melanoma cell lines, the pMel-S-
derived xenografts do not express CAR (data not shown). The
findings of our xenograft model were as follows: animals that
received Ad5/35-based therapy had significantly smaller
tumors than animals treated with the homologous Ad5-based
vectors. Furthermore, despite the poor intratumoral transduc-
tion efficiency of currently available replication-defective
viral vectors (Ram et al., 1997), we were able to demonstrate
in this model that the intratumoral injection of the replica-
tion-defective adenovirus vector encoding MV-H/F in com-
bination with DTIC resulted in a significantly higher
treatment efficacy than treatment with the individual
compounds. Lastly, our triple therapy consisting of MV-H/F
expression, chemotherapy, and trans-complementing onco-
lytic replication-restricted vectors significantly enhanced the
anti-neoplastic treatment efficacy when compared to single-
or double-agent therapy. Several factors, working in concert,
are responsible for this improved treatment efficacy: first, due
to the trans-complementation strategy (Dion et al., 1996;
Alemany et al., 1999; Wildner et al., 1999b; Lee et al., 2004;
Wolkersdorfer et al., 2004) a greater percentage of the tumor
cells expressed MV-H/F. The trans-complementation of
replication-defective adenovirus gene transfer vectors with a
helper virus is important for adenovirus vectors since most of
the replication-competent vectors cannot carry a therapeutic
gene due to size constraints. Second, oncolytic adenovirus
vectors can enhance the efficacy of chemotherapeutic agents
by themselves, as confirmed in our tumor model (Khuri et al.,
2000). Third, without using chemotherapy, several groups
previously reported that the intratumoral expression of MV-H/F
enhances the efficacy of virotherapy (Galanis et al., 2001;
Ahmed et al., 2003; Fu et al., 2003).
In summary, of the 21 analyzed adenovirus types and one
RGD fiber-modified Ad5 vector, Ad35 showed the highest
internalization efficiency in the tested melanoma cells. The
enhanced infectivity resulted in an enhanced therapeutic
efficacy. In addition, we demonstrated that the combination
of virotherapy, intratumoral expression of fusogenic mem-
brane glycoproteins, and chemotherapy was clearly superior
when compared to the treatment with its individual
components used alone or in combination. Gene therapy
with adenovirus targeted toward the Ad35 receptor may have
favorable therapeutic characteristics for future gene therapy
applications of melanoma.
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Figure 5. Kaplan–Meier survival analysis. The short-term cell culture
pMel-S, derived from a primary human cutaneous malignant melanoma,
was used to establish a subcutaneous xenograft model in nude mice. The
primary tumor as well as the derived short-term culture and the xenografts
were negative for the functional receptor of Ad5, the CAR (data only partially
shown). When xenografts reached a volume ofB200mm3, groups of 10 mice
were treated on day 0 and day 2 with a replication-defective adenovirus
encoding measles virus H and F (Ad5/35.H/F or Ad5.H/F) alone or in
combination with DTIC, and/or a replication-restricted oncolytic adenovirus
vector (Ad5/35D24.Ki COX or Ad5D24Ki COX). The vectors Ad5/35 and
Ad5 differed only in the fiber. For clarity, the survival plots were separated
into three graphs.
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MATERIALS AND METHODS
Cells and cell culture
The continuous human melanoma cell lines A375 (CRL-1619), 888
(CRL-7623), and Sk-Mel2 (HTB-68), the human lung carcinoma cell
line A549 (CCL-185), and the human cervix cancer cell line HeLa
(CCL-2) were obtained from the American Type Culture Collection
(Manassas, VA). The embryonal kidney cell line 293 was purchased
from Microbix (Toronto, ON). We established five short-term
cultures of melanoma cells from patients who underwent surgery
for treatment of histologically confirmed malignant melanoma,
designated pMel-A1, pMel-L, pMel-M, pMel-P, and pMel-S, as
described previously (Nettelbeck et al., 2004). All cells were grown
in high glucose DMEM supplemented with 10% heat-inactivated
fetal bovine serum, 50 mgml1 gentamicin, and 2mM glutamine
(Invitrogen/Gibco, Paisley, UK), at 371C, 5% CO2 in a humidified
incubator.
Viruses
Handling authorization for wild-type and recombinant adenoviruses
was obtained from local state authorities. Human adenovirus
prototype strains 3 (VR-3), 5 (VR-5), 7 (VR-7), 8 (VR-1368), 9 (VR-
1086), 11 (VR-12), 16 (VR-1093), 19 (VR-254), 20 (VR-255), 21 (VR-
1098), 22 (VR-1100), 25 (VR-223), 27 (VR-1105), 31 (VR-1109), 32
(VR-625), 34 (VR-716), 35 (VR-718), 37 (VR-929), 38 (VR-988), 49
(VR-1407), and 50 (VR-1501) were obtained from the American
Type Culture Collection. All viruses were propagated in A549 cells.
The replication-defective firefly luciferase encoding adenovirus
vectors Ad5.Luc, Ad5/3.Luc, and Ad5lucRGD have been described
previously (Dmitriev et al., 1998). In addition, we generated Ad5/
35.Luc by homologous recombination of the shuttle plasmid with the
Ad5 backbone plasmid pAdEasy-1/F35 and subsequent rescue of
infectious vector in 293 cells as described previously (He et al.,
1998). All luciferase encoding adenovirus vectors differed only in the
fiber gene and were propagated in 293 cells. To generate the tumor-
restricted replication-competent adenovirus vectors Ad5/
35D24.Ki COX and Ad5D24.Ki COX, the Ki67 (600/þ 7) (Duch-
row et al., 1996) and cyclooxygenase-2 (327/þ 59) (Inoue et al.,
2000) promoter were cloned into the transfer vector pShuttle#4-1 24,
and the plasmid vectors were generated in a single homologous
recombination step in Escherichia coli as described previously
(Hoffmann and Wildner, 2006b). The Ad5 backbone plasmid
pAd.Easy-1 (He et al., 1998) and the Ad5 backbone plasmid
pAdEasy-1/F35 (Nilsson et al., 2004) (kindly obtained from Xiaolong
Fan, Lund University, Lund, Sweden) encoded a chimeric long-
shafted fiber gene with the Ad5 fiber tail (nt 1–44) and Ad35 fiber
shaft and knob domains (nt 132–991). The oncolytic vectors were
produced in HeLa cells. The replication-defective adenovirus vectors
Ad5/35.H/F and Ad5.H/F encode the MV-H/F proteins under the
transcriptional control of the tumor-specific human telomerase
reverse transcriptase gene promoter (548/þ 5) (Horikawa et al.,
1999) as described previously (Hoffmann et al., 2006). Infectious
adenovirus vectors were rescued from plasmid vectors generated by
homologous recombination with pAdEasy-1/F35 or pAdEasy-1 in E.
coli, respectively. The vectors Ad5/35.H/F and Ad5.H/F were
generated and produced in 293 cells in the presence of the synthetic
fusion inhibitory peptide Z-D-Phe-Phe-Gly-OH (10 mM; Bachem AG,
Bubendorf, Switzerland) (Richardson et al., 1980). Adenovirus
particle concentrations were determined by measuring the optical
density at 260 nm (Maizel et al., 1968; Mittereder et al., 1996)
and expressed as viral particles (VPs) per milliliter. The infectious
titer was determined by plaque assay using 293 cells (Mittereder
et al., 1996). Viral vectors were purified with an ion-exchange
column purification kit (Vivapure AdenoPACK 100; Vivascience,
Hannover, Germany). The particle-to-plaque forming unit ratio
was B30:1.
Labeling of adenovirus and internalization assay
3H-thymidine labeling of adenovirus DNA and internalization assay
was carried out as described previously (Wickham et al., 1994;
Hoffmann et al., 2007d). Briefly, to determine the fraction of
internalized 3H-labeled adenovirus virions, 5,000 cells per well
were incubated for 1 hour with 5,000 VPs per cell of the labeled
virus (specific activity B104 c.p.m. per virion), followed by
extensive washing of the cell monolayers. To remove attached but
not internalized adenovirus, cells were incubated at 371C for
10minutes with 0.05% trypsin and 0.5mM EDTA in phosphate-
buffered saline (Shayakhmetov et al., 2000). After washing the cells,
internalized radiolabeled viral DNA was measured by scintillation
counting.
Immunohistochemistry and flow cytometry
Sampled melanoma specimen were formalin-fixed (10%), paraffin-
embedded, and sectioned (4 m) using standard procedures. For
immunohistochemical staining, sections were deparaffinized and
rehydrated. Endogenous peroxidase activity was blocked by
incubation for 20minutes in methanol containing 3% hydrogen
peroxide. For melanoma-specific staining, slides were incubated
with the antibody HMB45 (Dako, Glostrup, Denmark) (Gown et al.,
1986). Immunoreactivity was detected with the Dako REAL Envision
Detection System (Dako) according to the manufacturer’s instruc-
tions. After DAB detection, slides were counterstained in Harris
hematoxylin and cover-slipped according to standard procedures.
For analysis of CAR expression, slides were immunostained with the
primary antibody E1-1 (ab9891; Abcam plc, Cambridge, UK),
followed by staining with a secondary FITC-conjugated rabbit anti-
mouse antibody (ab6724; Abcam plc). The expression of CD46 was
detected using the FITC-conjugated antibody MEM-258 (ab28068;
Abcam plc) according to the manufacturer’s recommendations.
Digital images were taken with a high-resolution still camera
(Olympus DP50, Tokyo, Japan) attached to a fluorescence micro-
scope (Olympus BX51).
For flow cytometric analysis of CAR and CD46 expression, the
same antibodies were used as described for the immunohistochem-
istry. For detection of CD80, the FITC-conjugated antibody MEM-
233 (ab ab8239; Abcam plc) was used according to the manufac-
turer’s recommendations. Samples were assayed on a FACSCalibur
flow cytometer (Becton Dickinson Immunocytometry Systems,
Mansfield, MA) and CellQuest software (BD Biosciences, San
Jose, CA).
Analysis of combined drug effects
As described previously (Hoffmann et al., 2006; Hoffmann and
Wildner, 2006c), we quantitatively analyzed the interaction
between MV-H/F expression and chemotherapy in the A375, Sk-
Mel2, pMel-P, and pMel-S cells with the median-effect principle
(Chou and Talalay, 1984; Chou, 1991a). Thirty-six hours after
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treatment, cytotoxicity-induced death of the cells was determined by
bioluminescence using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega, Madison, WI). Briefly, cells were incubated with
serial dilutions of the Ad5/35.H/F vector or DTIC (medac GmbH,
Wedel, Germany) to determine their individual ED50 (dose level that
results in 50% cytotoxicity). Using the definition 6.022 1023 VPs
per liter¼ 1mol l1 (Mittereder et al., 1996), we calculated the
molarity for the vector Ad5/35.H/F based on the assumption that one
plaque forming unit equals one biologically active molecule (virion).
In the second step, cells were treated with combinations of Ad5/
35.H/F and DTIC at a fixed 1:1 ratio of serial dilutions of their
respective ED50 values. For each level of cytotoxicity (f¼ 0.95, 0.90,
y 0.05), a parameter called the CI was calculated using the software
CalcuSyn (Chou, 1991a). A CIo1 indicates synergism, while a
CI¼ 1 shows an additive effect, and CI41 indicates antagonism
(Chou and Talalay, 1984; Chou, 1991b). In this equation, the dose
reduction index defines the extent of drug dose reduction possible in
a combination for a given degree of effect, as compared with the
dose of each drug alone (Chou, 1991a, b).
In vivo studies
The Animal Care and Use Committee of the Ruhr-University
Bochum approved all described studies. Six- to eight-week-old
female nude mice (Balb/c nu/nu) were obtained from Janvier (Le
Genest-St-Isle, France). To establish a subcutaneous melanoma
xenograft model, nude mice received subcutaneously 1 107 pMel-S
cells in 100ml into the hind flanks. When the tumors reached a
volume ofB200mm3, animals were randomly assigned to treatment
groups (n¼ 10). Animals treated with the oncolytic viruses or the
MV-H/F encoding vectors alone or in combination with DTIC
(200mg kg1 body weight given in 1ml 0.9% NaCl solution
intraperitoneally once a day for 5 consecutive days starting on day
4) received intratumoral 6 109 VPs in a total volume of 100ml
phosphate-buffered saline on day 0, day 1, and day 2. Animals
treated with the oncolytic viruses in combination with Ad5.H/F or
Ad5/35.H/F received per treatment cycle 3 109 VPs plus 3 109
VPs alone or in combination with DTIC. At least once a week,
minimum and maximum perpendicular tumor axes were measured
using vernier calipers, and tumor volume was calculated using the
simplified formula of a rotational ellipse (lw2 0.5). The skin
thickness of 0.4mm was subtracted from the measurements. Animals
were maintained under specific pathogen-free conditions and were
euthanized with CO2 if their tumors exceeded 10% body weight or if
the mice appeared to be in distress.
Statistical methods and median-effect analysis
The statistical software package SPSS 15 (SPSS Inc., Chicago, IL) was
used to assess adenovirus internalization efficiency by one-way
analysis of variance followed by the Dunnett’s multiple comparison
test. Treatment efficacy was assessed by analyzing tumor volumes by
analysis of variance followed by the Tukey’s honestly significant
difference test and Kaplan–Meier analysis with the log-rank test for
survival analysis. The combined drug effects were analyzed by the
methods described by Chou and Talalay (1984) using the software
CalcuSyn 2.0 (Biosoft, Cambridge, UK).
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